OSLO, Norway, March 14, 2016 (GLOBE NEWSWIRE) — Targovax, a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management team will participate in the following life sciences and investor conferences:
INVESTOR/PARTNERING CONFERENCES
Sachs Associates 9th Annual ELSCEO Forum & Exhibition
Zurich, 15 March, 2016
Participants: Gunnar Gårdemyr (CEO), Øystein Soug (CFO) and Magnus Jäderberg (CMO)
Presentation time: 10:45
Venue: Hilton Zurich Airport Hotel
BIO-EUROPE Spring 2016
Stockholm, 5-6 April, 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)
BioEquity
Copenhagen, 10-11 May, 2016
Participants: Gunnar Gårdemyr (CEO), Øystein Soug (CFO) and Magnus Jäderberg (CMO)
BIO International Convention
San Francisco, 6-9 June, 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)
SCIENTIFIC CONFERENCES
Royal Swedish Academy of Engineering Sciences
Stockholm, 16 May, 2016
Participants: Magnus Jäderberg (CMO)
ASCO
Chicago, 3-7 June, 2016
Participants: Magnus Jäderberg (CMO)
The Presentations will be available to download at www.targovax.com following the event.
For further information, please contact:
Gunnar Gårdemyr
CEO
Phone: +41 798 340 585
Email: ggardemyr@targovax.com
Øystein Soug
CFO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
About Targovax: “Arming the patient’s immune system to fight cancer”
Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aim to become a leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology:
ONCOS - 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment may reinstate the immune system’s capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax works towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.
The product candidates will be developed in combination with multiple treatments in several cancer indications, including checkpoint inhibitors. Targovax also has a number of other cancer immune therapy candidates in the early stage of development. For more information go to www.targovax.com.
HUG#1994178
